

SHORT COMMUNICATION

Systematic review and meta-analysis of Japanese familial Alzheimer's disease and FTDP-17

Kensaku Kasuga^{1,2,6}, Masataka Kikuchi^{1,3,6}, Takayoshi Tokutake⁴, Akihiro Nakaya^{1,5}, Toshiyuki Tezuka⁴, Tamao Tsukie^{1,3}, Norikazu Hara¹, Akinori Miyashita¹, Ryoza Kuwano¹ and Takeshi Ikeuchi¹

Mutations in *APP*, *PSEN1* and *PSEN2* as the genetic causes of familial Alzheimer's disease (FAD) have been found in various ethnic populations. A substantial number of FAD pedigrees with mutations have been reported in the Japanese population; however, it remains unclear whether the genetic and clinical features of FAD in the Japanese population differ from those in other populations. To address this issue, we conducted a systematic review and meta-analysis of Japanese FAD and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) by literature search. Using this analysis, we identified 39 different *PSEN1* mutations in 140 patients, 5 *APP* mutations in 35 patients and 16 *MAPT* mutations in 84 patients. There was no *PSEN2* mutation among Japanese patients. The age at onset in Japanese FAD patients with *PSEN1* mutations was significantly younger than that in patients with *APP* mutations. Kaplan–Meier analysis revealed that patients with *MAPT* mutations showed a shorter survival than patients with *PSEN1* or *APP* mutations. Patients with mutations in different genes exhibit characteristic clinical presentations, suggesting that mutations in causative genes may modify the clinical presentations. By collecting and cataloging genetic and clinical information on Japanese FAD and FTDP-17, we developed an original database designated as Japanese Familial Alzheimer's Disease Database, which is accessible at <http://alzdb.bri.niigata-u.ac.jp/>.

Journal of Human Genetics (2015) 60, 281–283; doi:10.1038/jhg.2015.15; published online 19 February 2015

Mutations in *APP*, *PSEN1* and *PSEN2* as the genetic causes of familial Alzheimer's disease (FAD) have been found in various ethnic populations.^{1,2} In addition, patients with mutations in *MAPT* associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) have been shown to exhibit Alzheimer's disease (AD)-like phenotypes.^{3,4} Although a substantial number of FAD pedigrees have been reported in Japan, it is not yet clear whether the genetic and clinical features of FAD in the Japanese population differ from those in other ethnic populations. To characterize the genetic and clinical features of Japanese FAD and FTDP-17, we here performed a systematic review and meta-analysis, and developed an original database of Japanese FAD and FTDP-17.

To comprehensively review the previously reported Japanese FAD and FTDP-17 cases, we performed a systematic search for publications in PubMed and Ichushi, a bibliographic database of medical literature in Japanese. The terms 'familial Alzheimer', 'familial AD', 'FTDP-17', 'presenilin', '*PSEN1*', '*PSEN2*', '*APP*' and '*MAPT*' were used to search in PubMed, and the equivalent terms in Japanese were used to search in Ichushi. From the literature searches we found 60 English and 29 Japanese articles and/or abstracts that reported on Japanese FAD and FTDP-17 pedigrees bearing the causative mutations (Supplementary

Table 1). Using the information obtained by the systematic literature review, we developed an original database for Japanese FAD and FTDP-17 designated as Japanese Familial Alzheimer's Disease database (JFADdb). In the database, each of the mutations in *APP*, *PSEN1/2*, *MAPT* and *GRN* was described in accordance with the reference sequences.⁵ Information on age at onset, clinical manifestations, age at death and *APOE* genotype were included in the database (Supplementary Figure 1).

We identified 39 different *PSEN1* mutations in 140 patients, 5 *APP* mutations in 35 patients and 16 *MAPT* mutations in 84 patients (Table 1). Among them, 10 *PSEN1* mutations, 5 *APP* mutations and 11 *MAPT* mutations were not included in the well-known Alzheimer Disease and Frontotemporal Dementia Mutation database (<http://www.molgen.ua.ac.be/ADMutations/>).⁶ No *PSEN2* mutation has been found in Japanese FAD. The frequency of mutated genes in FAD patients in the Japanese population was not significantly different from those in other populations (χ^2 , $P = 0.99$).⁶ Most FAD pedigrees show autosomal dominant inheritance; however, an *APP* $\Delta E693$ mutation was responsible for a recessively inherited FAD.⁷ Sporadic occurrences of mutations were observed: five patients with *PSEN1* mutations, one patient with *APP* mutation and two patients with *MAPT* mutations.

¹Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan; ²Center for Transdisciplinary Research, Niigata University, Niigata, Japan; ³Research Association for Biotechnology, Tokyo, Japan; ⁴Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan and ⁵Department of Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan

⁶These authors contributed equally to this work.

Correspondence: Dr T Ikeuchi, Department of Molecular Genetics, Brain Research Institute, Niigata University, 1-757 Asahimachi, Niigata 951-8585, Japan.

E-mail: ikeuchi@bri.niigata-u.ac.jp

Received 7 November 2014; revised 7 January 2015; accepted 13 January 2015; published online 19 February 2015

Table 1 Summary of genetic features of Japanese FAD and FTDP-17

Disease	Genes	Number of mutations	Number of pedigrees	Number of patients
FAD	<i>PSEN1</i>	39	40	140
	<i>PSEN2</i>	0	0	0
	<i>APP</i>	5 ^a	13	35
FTDP-17	<i>MAPT</i>	16	29	84
	<i>GRN</i>	2	2	2

Abbreviations: FAD, familial Alzheimer's disease; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17.
^aAPP duplication was included.

In our analysis, the majority of mutations (73%) was observed in a single small pedigree. Considering that novel mutations in FAD tend to be reported rapidly, note that there may be publication bias in the frequency of mutations in the database. Although rare, there were two *GRN* mutations in patients with primary progressive aphasia and frontotemporal lobar degeneration (FTLD).⁸ Because the number of *GRN* mutations was too small, the patients with *GRN* mutations were excluded from further meta-analysis.

The ages at onset were 44 ± 8 years (mean \pm s.d.) in patients with *PSEN1* mutations ($n=87$), 54 ± 9 years in *APP* mutations ($n=23$) and 45 ± 10 years in *MAPT* mutations ($n=51$). These ages at onset of FAD in our analysis are consistent with those reported in other ethnic populations.^{6,9} The age at onset in patients with *APP* mutations was significantly older than those in patients with *PSEN1* or *MAPT* mutations (Figure 1a). The clinical phenotypes of patients with *MAPT* mutations were classified into three subgroups: FTLD,¹⁰ AD-like^{3,4} and progressive supranuclear palsy (PSP) phenotypes.⁸ The age at onset in patients with the FTLD or PSP phenotype was significantly younger than that with the AD-like phenotype (Supplementary Figure 2). *APOE* genotypes did not significantly modify the age at onset in patients with causative mutations (Supplementary Figure 3). There was no significant difference in age at death among the patients with mutations in the three genes (Figure 1b). The disease duration from age at onset to death in patients with *MAPT* mutations was significantly shorter than that with *PSEN1* mutations (Figure 1c). The survival of patients after the onset was analyzed by Kaplan–Meier estimation, which revealed that patients with *MAPT* mutations showed a shorter survival than patients with *PSEN1* or *APP* mutations (Supplementary Figure 4).

The clinical diagnosis of AD before the genetic testing was performed in 96% of patients with *PSEN1* mutations and 97% of patients with *APP* mutations (Supplementary Table 2). Notably, only 57% of patients with *MAPT* mutations were clinically diagnosed as having FTLD; 19% and 12% of patients with *MAPT* mutations were clinically diagnosed as having AD and PSP, respectively (Supplementary Table 2). This finding suggests that mutational screening of clinically diagnosed FAD patients should not only include *APP* and *PSEN1/2* mutations but also include *MAPT* mutations.

We next analyzed the frequency of each of the clinical manifestations including psychiatric symptoms, mood disorders, spastic paraparesis, parkinsonism and epilepsy/seizure (Figure 2). As expected, the frequencies of psychiatric symptoms and parkinsonism were significantly higher in patients with *MAPT* mutations. Spastic paraparesis, which is a characteristic symptom of 'variant AD with cotton-wool plaque pathology'^{11,12} was observed in 15% of patients with *PSEN1* mutations, whereas none of the patients with *APP* mutations exhibited spastic paraplegia. Epilepsy/seizure was described in 8% of patients with *PSEN1* and 6% of patients with *APP* mutations,




Figure 1 Age at onset and death, and disease duration in Japanese FAD and FTDP-17 patients. (a) Age at onset for patients grouped on the basis of *PSEN1*, *APP* and *MAPT* mutations. The horizontal line in the box indicates the median, the lower and upper boundaries of the box represent the lower and upper quartile boundaries, respectively, and whiskers are 1.5 times the interquartile range. Patients with *PSEN1* and *MAPT* mutation showed significantly younger age at onset than patients with *APP* mutations (** $P < 0.01$, ANOVA with *post hoc* Tukey's test). (b) Age at death of three groups with gene mutations. There was no significant difference in age at death among the groups. (c) Disease duration was defined as the period from age at onset to death. The disease courses of patients with *MAPT* mutations (7 ± 4 years, mean \pm s.d.) were significantly shorter than those with *PSEN1* mutations (11 ± 5) (* $P < 0.05$, ANOVA with *post hoc* Tukey's test). ANOVA, analysis of variance; FAD, familial Alzheimer's disease; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17.




Figure 2 Frequency of each clinical manifestation in patients with Japanese FAD and FTDP-17. We investigated the presence or absence of psychiatric symptoms, mood disorders, spastic paraplegia, parkinsonism and epilepsy/seizure by careful reading of the original papers. We determined the frequency of each of the clinical manifestations by counting the number of patients for whom the presence of the manifestation was described in literature. In case there was no description of the manifestation, the patient was not counted as manifesting the manifestation. The observed frequencies of causative gene mutation were significantly different from the expected frequencies determined by residual analyses for χ^2 statistical analysis ($*P < 0.05$, $**P < 0.01$). FAD, familial Alzheimer's disease; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17.

whereas none of the patients with *MAPT* mutations exhibited epilepsy/seizure. Previous studies showed that the frequency of seizure was relatively high in patients with early onset of AD,^{13,14} and low in patients with *MAPT* mutations.¹⁵ These findings suggest that epilepsy/seizure is closely associated with amyloid pathology, and that tauopathy alone may not be sufficient to cause epilepsy. Taken together, mutations in causative genes may modify the clinical presentations in patients with familial dementia.

In summary, we have comprehensively collected, cataloged and systematically meta-analyzed the data from currently available data on Japanese FAD and FTDP-17. We made all the results publicly available on the online database 'JFADdb'. The database may provide information useful for estimating the age at onset and the natural course of disease in future preventive or therapeutic trials of Japanese FAD.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work is supported in part by Grants-in-Aid for scientific research from Japan Society of Promotion of Science, Japan (26870209 to KK, 23591234 and 20372469 to TI) and Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan. We are grateful to Dr Hasegawa and Ms Fukaumi for their technical assistance.

- 1 Karch, C. M., Cruchaga, C. & Goate, A. M. Alzheimer's disease genetics: from the bench to the clinic. *Neuron* **83**, 11–26 (2014).
- 2 Guerreiro, R. J., Gustafson, D. R. & Hardy, J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. *Neurobiol. Aging* **33**, 437–456 (2012).
- 3 Rademakers, R., Dermaut, B., Peeters, K., Cruts, M., Heutink, P. & Goate, A. *et al*. Tau (*MAPT*) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. *Hum. Mutat.* **22**, 409–411 (2003).
- 4 Ikeuchi, T., Kaneko, H., Miyashita, A., Nozaki, H., Kasuga, K. & Tsukie, T. *et al*. Mutational analysis in early-onset familial dementia in the Japanese population.

- The role of PSEN1 and MAPT R406W mutations. *Dement. Geriatr. Cogn. Disord.* **26**, 43–49 (2008).
- 5 Pruitt, K. D., Brown, G. R., Hiatt, S. M., Thibaud-Nissen, F., Astashyn, A. & Ermolaeva, O. *et al*. RefSeq: an update on mammalian reference sequences. *Nucleic Acids Res.* **42**, D756–D763 (2014).
- 6 Cruts, M., Theuns, J. & Van Broeckhoven, C. Locus-specific mutation databases for neurodegenerative brain diseases. *Hum. Mutat.* **33**, 1340–1344 (2012).
- 7 Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A. & Kanemitsu, H. *et al*. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann. Neurol.* **63**, 377–387 (2008).
- 8 Ogaki, K., Li, Y., Takahashi, M., Ishikawa, K., Kobayashi, T. & Nonaka, T. *et al*. Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. *Parkinsonism Relat. Disord.* **19**, 15–20 (2013).
- 9 Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A. & Fox, N. C. *et al*. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. *Neurology* **83**, 253–260 (2014).
- 10 Foster, N. L., Wilhelmsen, K., Sima, A. A. F., Jones, M. Z. & D'Amato, C. J. *et al*. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. *Ann. Neurol.* **41**, 706–715 (1997).
- 11 Larner, A. J. & Doran, M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. *J. Neurol.* **253**, 139–158 (2006).
- 12 Tabira, T., Chui, D. H., Nakayama, H., Kuroda, S. & Shibuya, M. Alzheimer's disease with spastic paresis and cotton wool type plaques. *J. Neurosci.* **70**, 367–372 (2002).
- 13 Noebels, J. A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. *Epilepsia* **52**, 39–46 (2011).
- 14 Vossel, K. A., Beagle, A. J., Rabinovici, G. D., Shu, H., Lee, S. E. & Naasan, G. *et al*. Seizures and epileptiform activity in the early stages of Alzheimer disease. *JAMA Neurol.* **70**, 1158–1166 (2013).
- 15 Sperfeld, A. D., Collatz, M. B., Baier, H., Palmbach, M., Storch, A. & Schwarz, J. *et al*. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. *Ann. Neurol.* **46**, 708–715 (1999).



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies the paper on Journal of Human Genetics website (<http://www.nature.com/jhg>)